Atai Life Sciences BV

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company, which engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany.

Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company's approach of identifying (in many instances psychedelic) compounds that have been tested in previous human trials marginally de-risks its programs.

Atai Life Sciences N.V.: A First Take

ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining.

Atai Life Sciences And The Future Of Psychedelics For Mental Health

atai Life Sciences N.V. (NASDAQ:ATAI ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Florian Brand – Chief Executive Officer Srini Rao – Chief Scientific Officer Conference Call Participants Charles Duncan – Cantor Ritu Baral – Cowen Greg Weaver Hi everyone, I'm Greg Weaver, CFO of atai Life Sciences.

atai Life Sciences' (ATAI) CEO Florian Brand on Q1 2022 Results - Earnings Call Transcript

– Strong execution across atai's three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI), please note the first and second paragraphs, which contained statements referencing the 2022 IR financial results posting and executives on the video interview, as well as forward-looking statements, have been modified. The corrected release follows:

CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai investor relations website at https://ir.atai.life to view Q1'22 financial results and press release.

atai Life Sciences to Announce First-Quarter 2022 Financial Results

Standard BioTools Inc

Limelight Networks

Retractable Technologies

Penny stocks to buy according to these insiders. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? Insiders Threw Big Money At These 4 Stocks

Archer Aviation

Cerus

Compugen

Ginkgo Bioworks Holdings

Joby Aviation

Nano Dimension

Invitae

Quantum-Si

Zymergen

Are these Cathie Wood penny stocks a buy right now? The post 10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in April:

atai Life Sciences to Participate in Upcoming April Investor Conference

Adobe

COMPASS Pathways

Cybin

Delta Air Lines

GW Pharmaceuticals

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Lowe's

Mind Medicine MindMed

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q4 2021 Results - Earnings Call Transcript

–   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform

NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update.

atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March:

atai Life Sciences to Participate in Upcoming March Investor Conferences

- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February.

atai Life Sciences to Participate in Upcoming February Investor Conference

atai Life Sciences on Thursday announced Invyxis, a new program to accelerate the company's portfolio of compounds.

ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai's portfolio of new chemical entities (NCEs)

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 Psychedelic Therapeutics Decisions Coming in 2022

•  Enables expansion of PCN-101 clinical development to the U.S.

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today:

atai Life Sciences to Participate in Upcoming January Investor Conference

Field Trip Health Ltd

Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.

3 Psychedelic Stocks to Play the Shroom Boom

The stock price of ATAI Life Sciences NV (NASDAQ: ATAI) increased by over 11% today. This is why it happened.

ATAI Life Sciences Stock (ATAI): Why The Price Increased Over 11% Today

atai Impact's first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital's Center for the Neuroscience of Psychedelics

• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai's diversified platform and multiple innovative programs designed to address unmet patient need in mental health

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements

News for Atai Life Sciences BV Stock (ATAI)